Molecular Imaging, Pharmacokinetics, and Dosimetry of 111In-AMBA in Human Prostate Tumor-Bearing Mice
| Autor: | Yu-Hsien Wu, I-Hsiang Liu, Wan-Chi Lee, Lie-Hang Shen, Liang-Cheng Chen, Te-Wei Lee, Chun-Lin Chen, Chung-Li Ho, Cheng-Hui Chuang, Wuu-Jyh Lin, Chih-Hsien Chang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Biodistribution
Article Subject business.industry Health Toxicology and Mutagenesis lcsh:Biotechnology lcsh:R lcsh:Medicine General Medicine Effective dose (pharmacology) In vitro medicine.anatomical_structure Pharmacokinetics Prostate lcsh:TP248.13-248.65 Genetics medicine Molecular Medicine Distribution (pharmacology) Personalized medicine Molecular imaging business Nuclear medicine Molecular Biology Biotechnology |
| Zdroj: | Journal of Biomedicine and Biotechnology, Vol 2011 (2011) |
| ISSN: | 1110-7251 1110-7243 |
| Popis: | Molecular imaging with promise of personalized medicine can provide patient-specific information noninvasively, thus enabling treatment to be tailored to the specific biological attributes of both the disease and the patient. This study was to investigate the characterization of DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH2(AMBA)in vitro, MicroSPECT/CT imaging, and biological activities of111In-AMBA in PC-3 prostate tumor-bearing SCID mice. The uptake of111In-AMBA reached highest with3.87±0.65% ID/g at 8 h. MicroSPECT/CT imaging studies suggested that the uptake of111In-AMBA was clearly visualized between 8 and 48 h postinjection. The distribution half-life (t1/2α) and the elimination half-life (t1/2β) of111In-AMBA in mice were 1.53 h and 30.7 h, respectively. TheCmaxand AUC of111In-AMBA were 7.57% ID/g and 66.39 h∗% ID/g, respectively. The effective dose appeared to be 0.11 mSv/MBq-1. We demonstrated a good uptake of111In-AMBA in the GRPR-overexpressed PC-3 tumor-bearing SCID mice.111In-AMBA is a safe, potential molecular image-guided diagnostic agent for human GRPR-positive tumors, ranging from simple and straightforward biodistribution studies to improve the efficacy of combined modality anticancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|